APA (7th ed.) Citation

A, L., KN, M., D, B., A, I., EC, P., & JS, L. (2026). Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer. European journal of nuclear medicine and molecular imaging, 53(7), 4587. https://doi.org/10.1007/s00259-026-07820-7

Chicago Style (17th ed.) Citation

A, Loor, Mack KN, Bauer D, Ingham A, Pratt EC, and Lewis JS. "Minimal Chemical Modification Enables Alpha/beta Radiolabeling of Sacituzumab Govitecan for Targeted Therapy in High Grade Serous Ovarian Cancer." European Journal of Nuclear Medicine and Molecular Imaging 53, no. 7 (2026): 4587. https://doi.org/10.1007/s00259-026-07820-7.

MLA (9th ed.) Citation

A, Loor, et al. "Minimal Chemical Modification Enables Alpha/beta Radiolabeling of Sacituzumab Govitecan for Targeted Therapy in High Grade Serous Ovarian Cancer." European Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 7, 2026, p. 4587, https://doi.org/10.1007/s00259-026-07820-7.